|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/135 | |
| A61P 37/06 | |||
| A61K 31/397 |
| (11) | Number of the document | 1819326 |
| (13) | Kind of document | T |
| (96) | European patent application number | 05826219.7 |
| Date of filing the European patent application | 2005-11-28 | |
| (97) | Date of publication of the European application | 2007-08-22 |
| (45) | Date of publication and mention of the grant of the patent | 2014-07-02 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2005/043044 |
| Date | 2005-11-28 |
| (87) | Number | WO 2006/058316 |
| Date | 2006-06-01 |
| (30) | Number | Date | Country code |
| 631483 P | 2004-11-29 | US |
| (72) |
KOVARIK, John, M., CH
APPEL-DINGEMANSE, Silke, CH
|
| (73) |
Novartis Pharma GmbH,
Brunner Strasse 59, 1230 Wien,
AT
Novartis AG, Corporate Intellectual Property Lichtstrasse 35, 4056 Basel, CH |
| (54) | DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST |
| DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST |